surfactin
antivir
activ
variou
envelop
virus
inhibit
viral
membran
fusion
howev
potenti
util
surfactin
antivir
drug
limit
cytotox
studi
surfactin
analogu
obtain
chemic
synthesi
evalu
determin
antipedv
activ
hemolyt
activ
critic
micel
concentr
main
goal
studi
develop
safer
drug
surfactin
analogu
high
antipedv
activ
low
hemolyt
activ
compar
surfactin
one
analogu
develop
lower
hemolyt
activ
antivir
activ
select
index
si
surfactin
word
safe
effect
concentr
rang
time
greater
surfactin
like
surfactin
direct
antivir
effect
pedv
structur
linear
lipopeptid
three
carboxyl
group
surfactin
deriv
similar
could
obtain
lacton
bond
hydrolyz
surfactin
well
total
synthesi
surfactin
antivir
activ
varieti
envelop
virus
includ
herp
simplex
viru
vesicular
stomat
viru
vsv
simian
immunodefici
viru
siv
newcastl
diseas
viru
ndv
recent
demonstr
surfactin
exert
antivir
effect
inhibit
viral
membran
fusion
membran
fusion
viral
envelop
cell
membran
essenti
envelop
virus
invad
host
cell
surfactin
act
directli
viru
particl
insert
viral
envelop
lipid
bilay
therebi
reduc
membran
fusion
rate
addit
sinc
lipid
compon
viral
envelop
provid
host
cell
composit
structur
function
wide
similar
envelop
virus
surfactin
antivir
activ
numer
envelop
virus
promis
broadspectrum
antivir
reagent
howev
effect
dose
rang
surfactin
narrow
mere
x
antivir
concentr
caus
hemolysi
cytotox
studi
compar
chemic
synthes
surfactin
analogu
determin
futur
direct
surfactin
modif
surfactin
cyclic
lipopeptid
natur
produc
variou
strain
bacillu
subtili
structur
consist
seven
amino
acid
peptid
loop
hydrophob
fatti
acid
chain
product
design
surfactin
made
chang
number
composit
amino
acid
fatti
acid
proven
effect
strategi
screen
larg
number
lipopeptid
biolog
activ
current
research
focus
anticanc
antimicrobi
insulin
deliveri
properti
antivir
potenti
fatti
acid
chain
length
critic
antimicrobi
effect
synthet
polymyxin
analogu
specif
antimicrobi
spectrum
analogu
depend
amino
acid
lipopeptid
addit
synthet
daptomycin
analogu
introduct
aromat
group
fatti
acid
moieti
also
affect
antibacteri
activ
studi
seri
similar
lipopeptid
design
synthes
use
surfactin
templat
analogu
differ
number
hydrophob
amino
acid
number
hydrophil
group
charg
properti
amino
acid
chiral
posit
hydrophil
amino
acid
aromat
group
fatti
chain
porcin
epidem
diarrhea
viru
pedv
coronaviru
infect
pig
age
especi
virul
newborn
piglet
caus
diarrhea
dehydr
even
death
outbreak
pedv
report
mani
countri
caus
immeasur
loss
global
swine
industri
recent
research
lab
show
surfactin
act
directli
pedv
envelop
inhibit
fusion
process
host
cell
membran
studi
pedv
use
target
screen
chemic
synthes
surfactin
analogu
enhanc
antivir
properti
result
provid
theoret
basi
develop
new
surfactinderiv
antivir
drug
lipopeptid
synthes
synpeptid
co
ltd
shanghai
china
mass
spectrometri
use
determin
molecular
weight
confirm
product
sequenc
puriti
synthet
lipopeptid
sampl
hplc
ten
synthet
lipopeptid
sampl
name
sequenc
tabl
cercopithecu
aethiop
kidney
epitheli
cell
vero
atcc
cultur
high
glucos
dmem
gibco
us
supplement
fetal
bovin
serum
fb
gibco
c
co
humidifi
atmospher
cell
routin
seed
densiti
ml
vero
cell
seed
cellswel
tissu
cultur
plate
incub
h
approxim
confluenc
reach
pfu
pedv
mix
equal
volum
slp
dmem
dmem
alon
incub
minut
ad
well
vero
cell
incub
minut
cell
wash
time
dmem
overlaid
agar
incub
hour
cell
fix
formaldehyd
stain
crystal
violet
agar
overlay
remov
data
repres
biolog
replic
plaqu
assay
perform
triplic
valu
express
mean
standard
deviat
curv
fit
ec
calcul
graphpad
prism
use
log
inhibitor
vs
respons
equat
hemolyt
activ
measur
accord
method
describ
jingdan
modif
briefli
serial
dilut
slp
ad
ul
suspens
porcin
rbc
pb
follow
incub
h
cell
centrifug
g
min
ul
supernat
transfer
well
plate
optic
densiti
nm
measur
use
micropl
reader
infinit
pro
tecan
group
ltd
switzerland
hemolysi
calcul
use
formula
od
od
b
od
p
repres
optic
densiti
slptreat
sampl
neg
control
posit
control
respect
triton
use
posit
control
sampl
run
triplic
surfac
tension
measur
use
ring
method
sampl
freshli
prepar
test
flask
allow
stand
minut
surfac
tension
measur
made
use
surfac
tensiomet
hldlstii
henlida
co
ltd
china
linear
regress
drop
flat
area
perform
separ
surfac
tensionconcentr
curv
concentr
intersect
two
line
critic
micel
concentr
cmc
time
addit
assay
perform
accord
procedur
describ
modif
confluent
vero
cell
plate
infect
pfu
pedv
incub
hr
synchron
infect
inoculum
remov
ml
dmem
ad
well
cell
place
humidifi
incub
indic
time
point
surfactin
dielaidoylphosphatidylethanolamin
depe
avantipolarlipid
alabast
al
ad
dropwis
cell
viru
final
concentr
incub
hour
viral
nucleic
acid
protein
level
cell
measur
qrtpcr
westernblot
respect
data
shown
repres
independ
experi
total
rna
extract
cell
use
trizol
reagent
invitrogen
accord
manufactur
instruct
cdna
gener
revers
transcript
use
hiscript
tm
qrt
supermix
qpcr
vazym
accord
manufactur
instruct
pedv
nucleic
acid
level
assess
measur
viral
nucleoprotein
n
use
qrtpcr
takara
sybr
green
qpcr
kit
takara
primer
sequenc
follow
gene
level
calcul
use
compar
ct
method
normal
endogen
level
gapdh
boil
cell
lysat
subject
sdspage
transfer
pvdf
membran
roch
basel
switzerland
use
semidri
transfer
apparatu
ge
littl
chalfont
buckinghamshir
uk
membran
block
nonfat
milk
tb
contain
tbst
incub
overnight
antipedv
nprotein
monoclon
antibodi
median
diagnost
south
korea
dilut
tbst
bsa
membran
wash
min
tbst
follow
incub
h
rt
hrp
goat
antimous
igg
antibodi
abgent
san
diego
ca
usa
thrice
wash
min
tbst
membran
incub
ecl
reagent
thermo
waltham
usa
imag
use
system
biorad
hercul
ca
usa
nativ
surfactin
amphiphil
cyclic
lipopeptid
consist
heptadin
interlink
fatti
acid
use
nativ
structur
templat
design
surfactin
analogu
commerci
synthes
fig
consist
heptadien
ident
peptid
nativ
surfactin
fatti
acid
chain
length
nativ
surfactin
n
heptadin
link
fatti
acid
ci
amin
slp
one
two
fewer
hydrophob
amino
acid
respect
rel
one
fewer
hydrophil
amino
acid
free
carboxyl
cend
act
addit
hydrophil
group
replac
two
acid
amino
acid
slp
lysin
basic
amino
acid
version
contain
lamino
acid
two
hydrophil
amino
acid
distant
close
proxim
slp
ident
except
diphenyl
group
fatti
acid
moieti
mass
spectra
slp
shown
fig
consist
expect
molecular
weight
case
slp
puriti
exceed
slp
test
antipedv
activ
use
plaqu
reduct
assay
serial
dilut
slp
incub
equal
volum
pedv
aliquot
onto
precool
cell
plate
viru
adsorb
cell
slp
wash
away
adsorb
viru
particl
count
plaqu
form
assay
fig
result
fit
sigmoidcurv
plot
fig
slp
potent
antipedv
effect
differ
antipedv
effect
higher
potenc
surfactin
hemolysi
commonli
use
assess
biosafeti
lipopeptid
shown
fig
slp
rang
hemolyt
activ
surfactin
similar
suggest
number
hydrophob
amino
acid
littl
effect
hemolyt
activ
howev
modif
significantli
affect
activ
one
two
three
carboxyl
group
respect
hemolyt
activ
reduc
turn
addit
chiral
differ
distinguish
two
amino
acid
residu
differ
arrang
amino
acid
also
affect
hemolyt
activ
result
indic
amino
acid
composit
complet
determin
characterist
slp
noteworthi
unexpect
effect
porcin
erythrocyt
although
low
hemolyt
activ
prevent
precipit
red
blood
assay
condit
concentr
select
index
si
determin
ratio
cytotox
concentr
cc
effect
concentr
ec
shown
tabl
highest
secondhighest
si
valu
respect
given
antisediment
effect
porcin
blood
cell
select
promis
candid
although
stronger
antivir
activ
surfactin
si
lower
due
high
hemolyt
activ
cmc
calcul
measur
surfac
tension
slp
rang
concentr
shown
fig
surfac
tension
decreas
slp
concentr
increas
approach
lowest
valu
curv
exhibit
inflect
point
slp
concentr
reach
cmc
linear
regress
perform
independ
use
data
descend
part
curv
cmc
equilibrium
part
cmc
intersect
linear
regress
line
correspond
cmc
tabl
order
explor
relationship
cmc
antipedv
activ
hemolyt
activ
scatter
plot
pair
assay
fig
plot
contain
point
repres
characterist
indic
surfactin
distribut
point
obviou
regular
three
plot
linear
regress
result
signific
conclud
antipedv
hemolyt
activ
slp
examin
studi
relat
surfact
activ
repres
cmc
addit
signific
correl
antipedv
activ
hemolyt
activ
synthet
lipopeptid
combin
greater
antivir
activ
lower
cytotox
still
found
specif
structureact
relationship
need
elucid
sinc
promis
surfactin
analogu
chose
studi
time
addit
assay
perform
determin
whether
exert
antipedv
effect
stage
infect
surfactin
sinc
surfactin
act
directli
virion
experi
design
examin
event
earli
infect
process
fig
summar
experiment
plan
eight
treatment
test
briefli
surfactin
depe
ad
viru
alon
cell
alon
cell
viru
togeth
prior
infect
viru
adsorpt
viru
invas
h
post
infect
replic
hpi
sampl
harvest
hour
infect
analyz
measur
cellular
level
viral
protein
fig
viral
rna
fig
expect
normal
compon
cell
membran
depe
affect
pedv
replic
stage
surfactin
exhibit
antivir
activ
specif
stage
exampl
surfactin
present
throughout
experi
treatment
group
littl
pedv
replic
occur
indic
nucleic
acid
protein
level
true
treatment
group
indic
compound
act
directli
viru
antivir
mechan
surfactin
rule
sinc
pedv
replic
inhibit
differ
degre
treatment
group
wedgeshap
lipid
hydrophil
head
larger
crosssect
area
hydrophob
tail
potenti
membran
fusion
inhibitor
recent
studi
rigid
amphipath
fusion
inhibitor
compound
deoxyribos
acet
hydrophil
moieti
antihsv
effect
addit
recent
studi
antimicrobi
activ
synthet
lipopeptid
report
lipopeptid
two
four
posit
charg
carbon
atom
lipid
chain
potent
antimicrobi
activ
fatti
acid
chain
length
carbon
atom
posit
correl
antimicrobi
activ
also
posit
correl
hemolyt
activ
membran
select
factor
must
consid
design
new
lipopeptid
structurefunct
relationship
warrant
studi
investig
lipopeptid
contain
two
three
neg
charg
two
posit
charg
fatti
acid
chain
carbon
atom
lipopeptid
antivir
activ
previous
publish
studi
demonstr
surfactin
antivir
activ
membran
fusion
inhibitor
order
improv
viral
envelop
select
surfactin
design
analogu
alter
peptid
amino
acid
kept
length
fatti
acid
chain
carbon
atom
compar
one
addit
carboxyl
group
end
peptid
antivir
effect
similar
although
one
less
hydrophil
amino
acid
antivir
activ
increas
result
indic
hydrophil
portion
wedgeshap
lipid
need
size
appropri
better
antivir
function
addit
differ
order
two
amino
acid
antivir
potenc
time
greater
indic
complex
relationship
molecular
structur
antivir
effect
cation
properti
synthet
lipopeptid
thought
relat
antibacteri
hemolyt
activ
cation
lipopeptid
examin
studi
strongest
hemolyt
activ
consist
hypothesi
cyclic
lipopeptid
report
readili
lyse
bacteri
membran
linear
branch
lipopeptid
agreement
found
hemolyt
activ
linear
molecul
ident
amino
acid
sequenc
surfactin
slightli
weaker
surfactin
cyclic
structur
also
report
total
hydrophob
synthet
lipopeptid
invers
relat
hemolyt
activ
although
conclus
data
relat
sampl
result
support
conclus
rel
hydrophob
indic
hplc
retent
time
min
respect
howev
hemolyt
activ
significantli
relat
total
hydrophob
summari
synthes
surfactin
analogu
character
identifi
enhanc
antivir
properti
equal
exceed
surfactin
antipedv
activ
compound
greatli
reduc
hemolyt
activ
make
select
index
time
larger
respect
surfactin
howev
exhibit
peculiar
inhibit
red
blood
cell
sediment
therefor
promis
synthet
surfactin
analogu
compar
surfactin
structur
distinguish
linear
lipopeptid
addit
carboxyl
group
c
peptid
also
two
fewer
hydrophob
amino
acid
surfactin
reduc
cost
synthesi
littl
effect
antivir
activ
sinc
surfactin
shown
protect
piglet
pedv
challeng
vivo
antivir
properti
surfactin
analogu
need
test
furthermor
respect
futur
use
synthet
surfactin
control
amelior
infect
pig
broader
spectrum
physiolog
activ
surfactin
analogu
need
studi
side
effect
beyond
hemolyt
toxic
need
explor
studi
suggest
surfactin
analogu
object
indepth
studi
order
develop
safer
broadspectrum
famili
surfactin
antivir
agent
synthet
surfactin
analogu
improv
antipedv
properti
conceptu
lvfeng
yuan
qian
yang
pedv
genom
detect
qrtpcr
experi
repeat
three
time
normal
group
plot
mean
sd
p
p
twotail
ttest
reagent
compar
group
http
synthet
surfactin
analogu
improv
antipedv
properti
